Maria Chiara Sergi
A5032831124- Cancer Immunotherapy and Biomarkers
- Diabetes Treatment and Management
- Pancreatic and Hepatic Oncology Research
- Neutropenia and Cancer Infections
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Metabolism, Diabetes, and Cancer
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Economic and Financial Impacts of Cancer
- Immune cells in cancer
- Inflammatory Biomarkers in Disease Prognosis
- Heart Rate Variability and Autonomic Control
- Chronic Lymphocytic Leukemia Research
- Respiratory Support and Mechanisms
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Gastric Cancer Management and Outcomes
- Advanced Breast Cancer Therapies
- Renal Transplantation Outcomes and Treatments
- Ferroptosis and cancer prognosis
- Cardiovascular and exercise physiology
- Medication Adherence and Compliance
- Diabetes and associated disorders
- Hedgehog Signaling Pathway Studies
- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari
2021-2024
University of Bari Aldo Moro
1996-2023
Ospedale Garibaldi
2023
Luigi Sacco Hospital
1986-1996
University of Milan
1985
Abstract Purpose: No evidence exists as to whether type 2 diabetes mellitus (T2DM) impairs clinical outcome from immune checkpoint inhibitors (ICI) in patients with solid tumors. Experimental Design: In a large cohort of ICI recipients treated at 21 institutions June 2014 2020, we studied on glucose-lowering medications (GLM) for T2DM had shorter overall survival (OS) and progression-free (PFS). We used targeted transcriptomics subset explore differences the tumor microenvironment (TME) or...
Ipilimumab plus nivolumab (COMBO) is the standard treatment in asymptomatic patients with melanoma brain metastases (MBM). We report a retrospective study aiming to assess outcome of MBM treated COMBO outside clinical trials.
Brain metastasis in cutaneous melanoma (CM) has historically been considered to be a dismal prognostic feature, although recent evidence highlighted the intracranial activity of combined immunotherapy (IT). Herein, we completed retrospective study investigate impact clinical-pathological features and multimodal therapies on overall survival (OS) CM patients with brain metastases. A total 105 were evaluated. Nearly half developed neurological symptoms leading negative prognosis (p = 0.0374)....
Abstract Background Real-life spectrum and survival implications of immune-related adverse events (irAEs) in patients treated with extended interval dosing (ED) immune checkpoint inhibitors (ICIs) are unknown. Methods Characteristics 812 consecutive solid cancer who received at least 1 cycle ED monotherapy (pembrolizumab 400 mg Q6W or nivolumab 480 Q4W) after switching from canonical (CD; pembrolizumab 200 Q3W 240 Q2W) upfront were retrieved. The primary objective was to compare irAEs...
The favourable safety profile and the increasing confidence with immune checkpoint inhibitors (ICIs) might have boosted their prescription in frail patients short life expectancies, who usually are not treated standard chemotherapy.
<p>Tumour micron-environment transcriptome analysis.</p>
Leiomyosarcoma is a malignant smooth muscle neoplasm, which traditionally divided into superficial and deep tumors. Superficial leiomyosarcomas are quite rare entities, accounting for approximately 7% of soft tissue neoplasms 0.04% all cancers. Here we describe case advanced primary cutaneous leiomyosarcoma (PCL) in 93-year-old woman, highlighting the considerable size lesion correct surgical oncological management. The clinical story began about 4 years ago, neoplasia was treated only with...
COVID-19 pandemic revolutionized the way in which cancer patients are treated worldwide. Regarding neuro-oncological patients, usually considered frail and with lower life-expectancy respect to other oncological international scientific community had urgently reorganize treatment approach order minimize risk of in-hospital contagious. For GBM adjuvant treatments have been evaluated even much more attention regard expected efficacy. As a consequence, an hypofractioned radiotherapy regimen has...
Salivary gland tumors are relatively rare neoplasms, comprising approximately 3-6% of all head and neck tumors. Parotid carcinoma (PGC) represents 70-80% salivary malignancies. Treatment strategies depend on tumor histology, stage, molecular characteristics, with surgical resection adjuvant radiotherapy being the mainstays treatment for localized disease. Conversely, in advanced stages therapeutic approaches, including chemotherapy targeted agents, more challenging. We present a case report...
<p>Kaplan-Meier survival estimates according to the receipt of no diabetes medication, other medications/insulin therapy only, and metformin (either alone or in combinations). A) Overall Survival whole cohort; patients not receiving medications: 18.9 months (95%CI: 15.9-21.6; 684 events), on only: 19.3 11.6-22.9; 48 metformin: 12.3 9.8-15.9; 100 events). B) Progression Free 8.2 7.1-9.4; 872 10.7 6.7-11.6; 61 7.9 5.1-10.1; 124 events).</p>
<p>Kaplan-Meier survival estimates according to the receipt of other diabetes medications and insulin therapy. A) Overall Survival whole cohort; patients on oral antidiabetic drugs therapy: 17.5 months (95%CI: 12.8-20.9; 82 events), not receiving therapy 17.8 15.4 – 19.7; 750 events). B) Progression Free 8.2 6.2-11.4; 106 8.1 7.1 9.2; 951 events).</p>
<p>Kaplan-Meier survival estimates according to the receipt of metformin. A) Overall Survival whole cohort; patients on metformin: 12.4 months (95%CI: 10.5-16.3; 100 events), not receiving 19.0 16.4 – 21.1; 732 events). B) Progression Free 7.9 5.3-10.1; 124 8.3 7.3 9.5; 933 events).</p>